The authors concluded that partial correction of anaemia, with erythropoiesis-stimulating agents, improved fatigue in patients with end-stage renal disease, who were on dialysis. The evidence indicated improved fatigue outcomes, but the authors' conclusions may not be sufficiently cautious, due to a lack of well-designed studies.
on placebo, over six months. When this RCT was extended to an open-label design, starting or continuing patients on erythropoiesis-stimulating agents, for a further 12 months, patients formerly assigned to placebo experienced an 18% improvement in fatigue, and those already assigned to erythropoiesis-stimulating agents reported no further change in fatigue at 24 weeks. One RCT reported a greater improvement in fatigue scores with intravenous (18.6%) than with subcutaneous (11.1%) erythropoiesis-stimulating agents at 52 weeks. Two RCTs reported a non-significant deterioration (-0.2 to -6.6%) in low haemoglobin target groups, and a slight improvement in the high haemoglobin target group.
SF-36 vitality: One cohort study reported improvements in scores of 25% at 14 weeks and 23% at 16 weeks, after erythropoiesis-stimulating agents. One cohort study reported increased vitality at seven to 14 weeks of follow-up.
The results of the other scales were reported. By baseline haemoglobin: One RCT, of patients who had received erythropoiesis-stimulating agents, found significant differences between high and low baseline haemoglobin groups, at 96 weeks, for SF-36 vitality scores. Studies of lower baseline haemoglobin, with partial correction to a minimum haemoglobin of 10g/dL or more, reported an average 34.6% improvement in fatigue. Studies with a higher baseline haemoglobin, with an increase of 1g/dL or more, reported an average improvement of 5.5%. Studies with no change in haemoglobin (less than 1g/dL; control or placebo groups) reported an average decline of 0.7% in fatigue outcomes.
